NEW YORK, July 23, 2025 /PRNewswire/ — Azure Knowledge Corporation, a global provider of high-quality market research data since 2000, today announced the rebranding of its research arm as Mavrix, marking a strategic evolution in the company’s identity and mission.

Azure Knowledge Corporation Rebrands as Mavrix to Drive AI-Powered Data Intelligence

The rebranding to Mavrix reflects the company’s transformation into a modern data acquisition and intelligence firm. Mavrix specializes in a comprehensive range of data collection methodologies, including Online Panels/Communities, Phone/CATI, Face-to-Face Interviewing, Qualitative Services, Expert Networks, and Custom Recruitment, powered by industry-leading AI-based data quality and visualization tools.

Strategic Evolution for Global Leadership

“This rebrand responds to today’s shifting market landscape,” said Mavrix CEO Rafal Gajdamowicz. “We’re positioning Mavrix as a forward-thinking leader while staying true to our core values: quality, innovation, partnership, and client-focused service.”

The company has a global presence with leadership and operational teams across the U.S., Canada, Europe, and Asia, operating on six continents. They offer 24/7 support, local expertise, and deliver projects in 85+ countries in 40+ languages.

Technology Meets Human Expertise

By combining cutting-edge AI tools with human insight, Mavrix manages complex, multi-country projects using a wide spectrum of methodologies — from online surveys and in-person interviews to immersive environments and qualitative research.

Over 300 organizations worldwide — from Fortune 500s to startups and research firms — trust Mavrix for tailored solutions across finance, tech, healthcare, and consumer goods.

“We focus on building long-term, sustainable partnerships with our clients,” said Neil Blefeld, Managing Director of North America for Mavrix. “Our clients don’t just receive data — they gain insights that drive real advantage.”

Seamless Transition Strategy

The rebrand is being implemented in phases to ensure a smooth and uninterrupted experience for all stakeholders. A new website and refreshed visual identity will spotlight Mavrix’s expanded capabilities and its leadership in data-driven innovation.

Vision for Continued Excellence

Mavrix is committed to delivering transformative impact over the next 25 years in an increasingly complex business environment. Its strategy is designed to lead the industry while upholding the high standards that have defined its legacy. “Our focus is on our clients — 100% — to continue delivering excellence through advanced technologies and research methodologies,” said Glen Collins, EVP – Global Commercial Group.

About Mavrix

Mavrix is a global data and intelligence company offering tech-enabled research solutions. Formerly part of Azure Knowledge, it blends advanced technology with human expertise to deliver quality data and insights worldwide. www.mavrixdata.com

CHENGDU, China, July 23, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or “the Company”, HKEX: 6990) today announced that its partner, Windward Bio AG (“Windward Bio”) has launched its Phase 2 POLARIS clinical study, assessing long-acting dosing of SKB378/WIN378 for people living with asthma.

SKB378/WIN378 is a novel, recombinant fully human monoclonal antibody (mAb) that potently binds to the thymic stromal lymphopoietin (TSLP) ligand and inhibits the TSLP mediated signaling pathway by blocking the interaction between TSLP and TSLP receptor. This is a well-validated cytokine that plays a key role in the development and progression of a wide array of immunological conditions, including asthma and chronic obstructive pulmonary disease (COPD) where inhibition has demonstrated benefit in a wide array of inflammatory phenotypes. SKB378/WIN378 has been engineered to achieve an extended half-life and effector silencing and is subcutaneously administered. SKB378/WIN378 has been studied in a Phase 1 trial which confirmed the half-life for extended dosing, demonstrated a low rate of antidrug antibodies, and was safe and well tolerated up to the highest tested dose. 

The Phase 2 POLARIS trial is a global, randomized, double-blind, placebo-controlled study evaluating the dosing, safety, and efficacy of SKB378/WIN378 in patients with asthma. Initial data is expected in mid-2026. Additional clinical trials are planned with SKB378/WIN378 including in COPD in 2026. In January 2025, an IND application for SKB378/WIN378 for the treatment of COPD was approved by the National Medical Products Administration (NMPA).

SKB378/WIN378 started as a co-development project jointly conducted by the Company and Harbour BioMed (also known as HBM9378), with both parties equally sharing global rights. In January 2025, it was announced that the Company and Harbour BioMed had entered into an exclusive license agreement with Windward Bio, under which the Company and Harbour BioMed granted Windward Bio an exclusive license for the research, development, manufacturing and commercialization of SKB378/WIN378 globally (excluding Greater China and several Southeast and West Asian countries).

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world’s leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/.

About Windward Bio

Windward Bio is a clinical-stage biotechnology company with deep discovery, development and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions. Its lead program is WIN378, a potential best-in-disease, long-acting, anti-TSLP monoclonal antibody in Phase 2 for asthma. The company is planning additional clinical studies of WIN378 in COPD and other respiratory indications and is also building a pipeline of long-acting bi-specifics targeting validated biology in respiratory and dermatological conditions. Windward Bio launched earlier this year with a $200M Series A led by top-tier investors.

CHENGDU, China, July 23, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or “the Company”, HKEX: 6990) today announced that its partner, Windward Bio AG (“Windward Bio”) has launched its Phase 2 POLARIS clinical study, assessing long-acting dosing of SKB378/WIN378 for people living with asthma.

SKB378/WIN378 is a novel, recombinant fully human monoclonal antibody (mAb) that potently binds to the thymic stromal lymphopoietin (TSLP) ligand and inhibits the TSLP mediated signaling pathway by blocking the interaction between TSLP and TSLP receptor. This is a well-validated cytokine that plays a key role in the development and progression of a wide array of immunological conditions, including asthma and chronic obstructive pulmonary disease (COPD) where inhibition has demonstrated benefit in a wide array of inflammatory phenotypes. SKB378/WIN378 has been engineered to achieve an extended half-life and effector silencing and is subcutaneously administered. SKB378/WIN378 has been studied in a Phase 1 trial which confirmed the half-life for extended dosing, demonstrated a low rate of antidrug antibodies, and was safe and well tolerated up to the highest tested dose. 

The Phase 2 POLARIS trial is a global, randomized, double-blind, placebo-controlled study evaluating the dosing, safety, and efficacy of SKB378/WIN378 in patients with asthma. Initial data is expected in mid-2026. Additional clinical trials are planned with SKB378/WIN378 including in COPD in 2026. In January 2025, an IND application for SKB378/WIN378 for the treatment of COPD was approved by the National Medical Products Administration (NMPA).

SKB378/WIN378 started as a co-development project jointly conducted by the Company and Harbour BioMed (also known as HBM9378), with both parties equally sharing global rights. In January 2025, it was announced that the Company and Harbour BioMed had entered into an exclusive license agreement with Windward Bio, under which the Company and Harbour BioMed granted Windward Bio an exclusive license for the research, development, manufacturing and commercialization of SKB378/WIN378 globally (excluding Greater China and several Southeast and West Asian countries).

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world’s leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/.

About Windward Bio

Windward Bio is a clinical-stage biotechnology company with deep discovery, development and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions. Its lead program is WIN378, a potential best-in-disease, long-acting, anti-TSLP monoclonal antibody in Phase 2 for asthma. The company is planning additional clinical studies of WIN378 in COPD and other respiratory indications and is also building a pipeline of long-acting bi-specifics targeting validated biology in respiratory and dermatological conditions. Windward Bio launched earlier this year with a $200M Series A led by top-tier investors.

NEW YORK, July 23, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. The NYSE is participating at the All In and Hill and Valley’s “Winning the AI Race” Summit, capturing insights from key voices shaping the future of business, technology, and innovation.  

Ashley Mastronardi delivers the pre-market update on July 23rd

• Stocks are fractionally higher Wednesday morning after President Trump announced a “massive deal” with Japan. This move includes a reciprocal tariff of 15% on exports to the U.S. and Japan investing $550 Billion to the U.S.
• Investors are also paying attention to a slew of earnings throughout the day including NYSE-listed telecommunications giant AT&T. Tesla and Alphabet headline earnings after market close.
• Consumer intelligence company NielsenIQ celebrates its IPO at the NYSE this morning. The company, which raised over $1 billion, will ring the opening bell and begin trading under the ticker symbol NIQ.
• The NYSE is participating in the All In and Hill & Valley “Winning the AI Race” Summit in Washington D.C., engaging with influential leaders and innovators to gather strategic insights on the evolving intersection of AI, business, and technology.  

Opening Bell
NielsenIQ (NYSE: NIQ) celebrates its initial public offering

Closing Bell
Gotham FC celebrates becoming the first American women’s pro soccer club to win a continental competition 

Click here to download the NYSE TV App

Video – https://mma.prnasia.com/media2/2736810/NYSE_Market_Update_July_23.mp4 

NEW YORK, July 23, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. The NYSE is participating at the All In and Hill and Valley’s “Winning the AI Race” Summit, capturing insights from key voices shaping the future of business, technology, and innovation.  

Ashley Mastronardi delivers the pre-market update on July 23rd

• Stocks are fractionally higher Wednesday morning after President Trump announced a “massive deal” with Japan. This move includes a reciprocal tariff of 15% on exports to the U.S. and Japan investing $550 Billion to the U.S.
• Investors are also paying attention to a slew of earnings throughout the day including NYSE-listed telecommunications giant AT&T. Tesla and Alphabet headline earnings after market close.
• Consumer intelligence company NielsenIQ celebrates its IPO at the NYSE this morning. The company, which raised over $1 billion, will ring the opening bell and begin trading under the ticker symbol NIQ.
• The NYSE is participating in the All In and Hill & Valley “Winning the AI Race” Summit in Washington D.C., engaging with influential leaders and innovators to gather strategic insights on the evolving intersection of AI, business, and technology.  

Opening Bell
NielsenIQ (NYSE: NIQ) celebrates its initial public offering

Closing Bell
Gotham FC celebrates becoming the first American women’s pro soccer club to win a continental competition 

Click here to download the NYSE TV App

Video – https://mma.prnasia.com/media2/2736810/NYSE_Market_Update_July_23.mp4 

STUART, Fla., July 23, 2025 /PRNewswire/ — Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, is proud to announce it will host an exclusive half-day Summit on January 20, 2026, from  11:30 a.m. to 4:30 p.m. (CET) at the prestigious Belvedere Hotel in Davos, Switzerland, alongside the week of the World Economic Forum (WEF) Annual Meeting.

The World Economic Forum, held each January in Davos, is one of the world’s most prestigious gatherings of global leaders from business, government, academia, and civil society. It serves as a unique platform for shaping global, regional, and industry agendas.

Health In Tech’s hosting of a standalone summit at Davos signals its rising influence and its mission to lead global dialogue on equitable, tech-powered healthcare infrastructure.  

This premier event will bring together a curated group of over 75 global decision-makers, including insurance brokers, third-party administrators (TPAs), general agencies, hospital executives, wellness, technology and finance partners.

Attendees will join exclusive conversations and curated panels on next-generation underwriting, the convergence of wearables and data-driven health, value-based plan design, embedded insurance, and transformative financing models that are reshaping global healthcare access.

Health In Tech’s presence not only affirms its credibility on the global stage but accelerates its vision of democratizing care and streamlining insurance delivery through technology. Hosting this independent event in Davos is a strategic opportunity to contribute ideas, forge partnerships, and advancing innovations that can positively impact industries and societies worldwide.

This year’s 2026 summit marks a continuation of Health In Tech’s strong presence at the World Economic Forum, following its active involvement in the 2024 and 2025 Annual Meetings where CEO Tim Johnson and CFO Julia Qian were featured speakers at side events focused on insurance modernization and healthcare innovation.

“Davos is where global ideas gain momentum,” said Tim Johnson, Founder and CEO of Health In Tech. “We’re not just attending, we’re convening. By hosting our own summit, we’re giving our partners, clients, and investors a front-row seat to where the industry is heading. Together, we’ll explore the breakthroughs and partnerships that will shape the future of InsurTech and healthcare delivery.”

Julia Qian, CFO of Health In Tech, echoed the enthusiasm and highlighted the value of creating spaces for collaboration:

“When I spoke on a panel in Davos in 2024, I experienced the incredible energy and insights that come from gathering industry leaders in one place,” said Julian Qian, CFO of Health In Tech. “I’m excited for us now to host our own Summit in 2026 to help drive important conversations that will shape the future of health and insurance technology.”

The Health In Tech Davos Summit aims to foster strategic dialogue and collaboration among industry stakeholders, reinforcing the company’s commitment to being at the forefront of healthcare and insurance innovation.

About Health In Tech 

Health In Tech (Nasdaq: “HIT”) is an Insurtech platform company backed by third-party AI technology, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, and TPAs. Learn more at healthintech.com.

Investor Contact
Investor Relations
ir@healthintech.com

STUART, Fla., July 23, 2025 /PRNewswire/ — Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, is proud to announce it will host an exclusive half-day Summit on January 20, 2026, from  11:30 a.m. to 4:30 p.m. (CET) at the prestigious Belvedere Hotel in Davos, Switzerland, alongside the week of the World Economic Forum (WEF) Annual Meeting.

The World Economic Forum, held each January in Davos, is one of the world’s most prestigious gatherings of global leaders from business, government, academia, and civil society. It serves as a unique platform for shaping global, regional, and industry agendas.

Health In Tech’s hosting of a standalone summit at Davos signals its rising influence and its mission to lead global dialogue on equitable, tech-powered healthcare infrastructure.  

This premier event will bring together a curated group of over 75 global decision-makers, including insurance brokers, third-party administrators (TPAs), general agencies, hospital executives, wellness, technology and finance partners.

Attendees will join exclusive conversations and curated panels on next-generation underwriting, the convergence of wearables and data-driven health, value-based plan design, embedded insurance, and transformative financing models that are reshaping global healthcare access.

Health In Tech’s presence not only affirms its credibility on the global stage but accelerates its vision of democratizing care and streamlining insurance delivery through technology. Hosting this independent event in Davos is a strategic opportunity to contribute ideas, forge partnerships, and advancing innovations that can positively impact industries and societies worldwide.

This year’s 2026 summit marks a continuation of Health In Tech’s strong presence at the World Economic Forum, following its active involvement in the 2024 and 2025 Annual Meetings where CEO Tim Johnson and CFO Julia Qian were featured speakers at side events focused on insurance modernization and healthcare innovation.

“Davos is where global ideas gain momentum,” said Tim Johnson, Founder and CEO of Health In Tech. “We’re not just attending, we’re convening. By hosting our own summit, we’re giving our partners, clients, and investors a front-row seat to where the industry is heading. Together, we’ll explore the breakthroughs and partnerships that will shape the future of InsurTech and healthcare delivery.”

Julia Qian, CFO of Health In Tech, echoed the enthusiasm and highlighted the value of creating spaces for collaboration:

“When I spoke on a panel in Davos in 2024, I experienced the incredible energy and insights that come from gathering industry leaders in one place,” said Julian Qian, CFO of Health In Tech. “I’m excited for us now to host our own Summit in 2026 to help drive important conversations that will shape the future of health and insurance technology.”

The Health In Tech Davos Summit aims to foster strategic dialogue and collaboration among industry stakeholders, reinforcing the company’s commitment to being at the forefront of healthcare and insurance innovation.

About Health In Tech 

Health In Tech (Nasdaq: “HIT”) is an Insurtech platform company backed by third-party AI technology, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, and TPAs. Learn more at healthintech.com.

Investor Contact
Investor Relations
ir@healthintech.com

• Fully Unmanned— CURECA™, the 100% Automated Diagnostic System Defining the Future Gold Standard, Debuts in Chicago, July 28–31
• Unifying global diagnostic data – STAgora™, the big data platform set to transform the future of diagnostics
• Pilot partnerships to offer early access to the new diagnostic paradigm, with selected institutions engaged by year-end

SEOUL, South Korea, July 23, 2025 /PRNewswire/ — Seegene Inc., a global leader in molecular diagnostics, announced today that it will unveil its fully automated PCR testing system, CURECA™, and its data analytics platform, STAgora™, at ADLM 2025 (Association for Diagnostics & Laboratory Medicine), the world’s largest diagnostics conference, taking place in Chicago from July 28 to 31. With the introduction of these new technologies, Seegene declares a transformative shift in the global diagnostics paradigm.

Automating every step of PCR Testing for enhanced efficiency and accuracy

CURECA™ is the world’s first system to fully automate the entire PCR testing process – from specimen storage and pre-treatment to nucleic acid extraction, amplification, and result analysis – without any human intervention. Designed for 24/7 continuous operation, the system minimizes human error and dramatically improves the consistency and reliability of the test results.

A key breakthrough lies in its fully automated prep module, which addresses one of the most burdensome and error-prone stages in diagnostic workflows. Pre-treatment has traditionally been a major challenge, particularly when dealing with diverse sample types such as urine, blood, sputum, and stool. Lab technicians often carry out repetitive manual tasks over extended hours, and variations in skill level can result in inconsistent outcomes. Stool samples, especially, have posed serious automation barriers due to their viscosity and particulates, requiring heavy manual handling.

The prep module of CURECA™ system is the first to fully automate pre-treatment process across all major specimen types – including stool – overcoming longstanding obstacles in laboratory operations. This innovation reduces labor demands, expands sample throughput, and enhances overall operational and cost efficiency. It also shifts the role of laboratory personnel from manual processing to higher-level responsibilities, such as data analysis and clinical interpretation – helping labs better leverage their workforce in high-volume testing environments.

In addition, the prep module is applicable beyond PCR diagnostics. It supports pre-treatment for other disciplines, including clinical chemistry and immunoassays, marking a significant step forward in automation across the broader diagnostics market. Its modular architecture allows for flexible configuration and deployment tailored to the size, layout, and needs of each laboratory.

STAogra™ – Real-Time Global Data Integration Empowering Personalized Care

Also unveiled at ADLM 2025, STAgora™ is Seegene’s statistical platform that collects and analyzes real-time PCR diagnostic data to support clinical decision-making. By aggregating test data uploaded from hospitals around the world, the platform provides integrated insights into regional infection trends, hospital-level positivity rates, and patterns of co-infection. It also offers more than 40 statistical tools tailored for clinical support.

With STAgora™, healthcare providers can compare individual patient test results with local and regional epidemiological data, enabling more precise, data-driven treatment strategies. The platform allows clinicians to evaluate infection trends at both patient and community levels, improving the accuracy and speed of diagnosis and care planning. By delivering rapid, reliable insights through this kind of comprehensive analysis, STAgora™ is expected to become an essential analytical tool for clinical decision-making.

Expanding Global Collaboration via Technology Sharing and Strategic Partnerships

Building on its presence at ADLM 2025, Seegene aims to broaden access to CURECA™ and STAgora™ by offering early pilot experiences and establishing new global partnerships.

Earlier this year, CURECA™ attracted strong interest at ESCMID Global 2025, one of Europe’s leading clinical microbiology and infectious disease congresses. To strengthen its R&D and manufacturing capacity in the United States, Seegene has established local subsidiaries, including Seegene Technologies and Seegene CURECA.

“CURECA™ and STAgora™ are more than just diagnostics equipment or software—they represent a new global standard that will redefine diagnostics in clinical settings around the world. We will continue to share the many technological assets we’ve built over the years and based on this foundation, we are committed to driving fundamental innovation across the global diagnostics ecosystem.” Said Daniel Shin, Executive Vice President, Chief of Global Sales & Marketing at Seegene.

Disclaimer

The product is currently in a pre-commercialization phase. The configuration presented at ADLM 2025 is for demonstration purposes only and may differ in functionality, specifications, and components from the final commercial version. This material is intended solely to introduce the technology and does not constitute an advertisement for product sales.

About Seegene

Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene’s syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information.

Visit: Seegene.com and follow linkedin.com/company/seegene-inc